SPCC/LinkedIn
Jan 3, 2025, 12:28
Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond – SPCC
SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond – 29 January 2025, 18:00 CET.
Save the date!
Main topics:
∙ Review of the latest HR+ HER2- MBC data and description of the current and future treatment landscape
∙ Biomarker testing.
∙ Biomarker vs non-biomarker driven treatment choices.
∙ Optimal sequencing the current and future dependant on clinical characteristic (which?)
Register now (free of charge).
This webinar is supported by an unrestricted educational grant from Eli Lilly.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 1, 2025, 09:08
Feb 1, 2025, 09:02
Feb 1, 2025, 08:53
Feb 1, 2025, 08:46